Field Medical Secures $35M Series B Financing to Advance FieldForce PFA Platform for Ventricular Tachycardia and Atrial Fibrillation

Jul 02, 2025 22:15 CST Updated 22:15

Field Medical

Developer of Pulsed Electric Field Catheter Ablation Technology

Field MedicalAnnouncementCompleted a $35 million Series B financing round. This round of financing was led byBioStar Capital、Cue GrowthCo-led,Existing strategic investors continue to follow up. The funds raised will mainly be used forLaunch the pivotal VERITAS clinical trial, advanceFieldForceDevelopment of ablation systems, strengthening clinical and registration application capabilities.

Investor Evaluation

"Field MedicalThe transformative technology is tackling the most challenging and long-unmet clinical needs in cardiology, showcasing a rare level of innovative ambition. With a physician-led team offering precise clinical insights, the FieldForce platform delivers truly effective solutions. We are honored to support the company in advancing a new chapter in VT treatment innovation.

---Louis Cannon BioStar CapitalFounder and Senior Managing Director

Executive Evaluation

"VT is one of the areas with the lowest treatment penetration rates in the electrophysiology field, and clinicians still lack effective tools. Excitingly, the current VT field is re-emerging with the early pattern of the AF market — a huge gap between strong clinical demand and existing technology. We are accelerating the preparation of pivotal trials through a new generation of therapies that combine efficiency, precision, and clinical effectiveness, reshaping the possibilities for VT treatment in high-risk patients."

---Steven Mickelsen Founder and CEO of Field Medical

"This round of financing demonstrates the market's recognition of Field Medical's development momentum, which is not only due to clinical outcomes but also based on solid commercial fundamentals. Our impressive performance at the Heart Rhythm Society meeting attracted attention from institutional investors and strengthened continued support from existing investors, fully proving the market's high confidence in our technological roadmap, strategic layout, and management team.

---Oskar Dadason Field MedicalChief Financial Officer

Among arrhythmias, ventricular tachycardia (VT) and atrial fibrillation (AF) are two of the most common and serious types of arrhythmia diseases, which may lead to stroke, heart failure, sudden cardiac death, and drive up healthcare costs. In the United States and Europe, there are over 6 million patients with VT and premature ventricular contractions (PVCs), while AF affects approximately 2%-6% of the global population.

Nowadays, PFA ablation in the field of atrial fibrillation has become extremely competitive, andThere are currently no PFA products approved for marketing in the field of ventricular tachycardia. Relatively speaking,The field of ventricular tachycardia remains a blue ocean, and traditional thermal ablation inThe efficacy of ventricular tachycardia is not ideal.

ThereforeIn the field of ventricular tachycardia, PFA ablation will become the key focus in the future of electrophysiology. Currently, Medtronic (Sphere-9), Boco (FaraFlex) etc. have already enteredVentricular tachycardia, this niche track, and initiate clinical research. CurrentlyField Medical is located in ChinaThe First Tier of PFA Ablation in the Field of Ventricular Tachycardia in China This YearHRS 2025 Meeting Room AnnouncementFieldForce TreatmentFIM Study Data on Ventricular Tachycardia, Excellent Clinical Trial Results Key to Securing This Round of Financing

FieldForce

FieldForceYesField MedicalThe core products, including catheters and energy generators.FieldForceYesThe world's first dedicated contact force focal PFA catheter,Can achieve instantaneous ablation operation (treatment time only takes milliseconds).Seconds). ItsOvercomeThe limitations of the first-generation PFA technology and the significant unmet need for treating any arrhythmia, capable of treating not only atrial fibrillation but also complex ventricular arrhythmias.

To achieve one catheter for all treatmentsArrhythmia issues,Field MedicalDevelop a new technologyFieldBending, andFieldBendingTechnology forFieldForce。

FieldBendingA technique that predictably focuses energy around the catheter and reduces unwanted far-field effects, thereby enhancing efficacy and safety. Ultimately,FieldBendingThe ultra-targeted energy allows for more accurate and concentrated application of power to the target tissue, enabling the energy to penetrate deeper into the tissue and achieve a wider range of ablation.

Field Medical

Field MedicalIs an innovative company focused on the field of pulsed field catheter ablation. Founded by Dr. Steven Mickelsen in 2022, it is developing a patented technology called FieldBending, which aims to concentrate therapeutic effects and reduce the harmful far-field effects associated with first-generation PFA technology.Field MedicalAiming to expand the indications of pulsed field ablation (PFA) beyond atrial fibrillation treatment by addressing more challenging ventricular arrhythmias and common procedures such as supraventricular tachycardia (SVT) that require minimal sedation.